Nasdaq ctso.

As of April 24, 2023, the average one-year price target for Cytosorbents is 8.57. The forecasts range from a low of 5.56 to a high of $16.80. The average price target represents an increase of 261 .../PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac... CTSO : 3.21 (+2.56%) CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications PR Newswire ...CTSO Latest Pre Market Trades. Select time range to see more trades: Last 100 Trades. Pre-Market Time (ET) Pre-Market Price. Pre-Market Share Volume. 08:27:28. $1.47. 6.See the latest CytoSorbents Corp stock price (NASDAQ:CTSO), related news, valuation, dividends and more to help you make your investing decisions.

Nov 29, 2023 · Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. About the company. CTSO fundamental analysis. Snowflake Score.

PRINCETON, N.J., Jan. 31, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, issues a stockholder letter from its Chief Executive Officer, Dr. Phillip Chan ...PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using ...

PRINCETON, N.J., June 2, 2022 /PRNewswire/ -- CytoSorbents, Inc. (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will host its Annual Meeting virtually on Tuesday, June 7, 2022, at 10:00 a.m. Eastern. Stockholders of record as of April 14, 2022 will be able to …Oct 7, 2022 · PRINCETON, N.J., Oct. 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ... A look at the shareholders of Cytosorbents Corporation (NASDAQ:CTSO) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership.If you want to know who really controls Cytosorbents Corporation (NASDAQ:CTSO), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the ...

CytoSorbents (NASDAQ:CTSO) reported its Q3 earnings results on Thursday, November 9, 2023 at 04:15 PM.. Here's what investors need to know about the announcement. Earnings. CytoSorbents missed ...

Shares of CytoSorbents ( CTSO 4.27%) were getting clobbered on Tuesday, with the stock sinking 15.9% as of 3:14 p.m. EDT. The big decline came after the maker of blood purification technologies ...

MONMOUTH JUNCTION, N.J., July 31, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the ...CytoSorbents (NASDAQ:CTSO) Historical Stock Chart From Oct 2023 to Nov 2023 CytoSorbents (NASDAQ:CTSO) Historical Stock Chart From Nov 2022 to Nov 2023 Latest CTSO MessagesAbout CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood ...Cytosorbents Co. (NASDAQ:CTSO – Free Report) – Zacks Small Cap lowered their FY2023 EPS estimates for shares of Cytosorbents in a note issued to investors on Tuesday, November 14th.By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT CytoSorbents Corporation (NASDAQ:CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and ...

Dec 4, 2023 · In the previous quarter, Cytosorbents (NASDAQ:CTSO) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. CTSO's actual earnings. With 6.1% and 4.9% of the shares outstanding respectively, BlackRock, Inc. and The Vanguard Group, Inc. are the second and third largest shareholders. Furthermore, CEO Phillip Chan is the owner of ...We feel now is a pretty good time to analyse Cytosorbents Corporation's (NASDAQ:CTSO) business as it appears the company may be on the cusp of a considerable accomplishment. Cytosorbents ...CTSO After-Hours Quotes. Data is delayed at least 15 minutes. Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of ...By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT CytoSorbents (NASDAQ:CTSO) reported 3rd quarter 2023 results on November 9th which showed strong product revenue growth. 3rd quarter product revenues increased 20% to $7.8 million and grant income decreased 35.9%. The increase in the Euro to U.S. dollar …About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood ...

About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, ...

Read Our Latest Report on Cytosorbents. Cytosorbents Stock Performance. NASDAQ CTSO opened at $1.24 on Thursday. The stock has a market cap of $55.11 million, a P/E ratio of -2.34 and a beta of 0.79.Of the 27 institutional investors that sold Cytosorbents stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: State Street Corp ($0.57M), Redmile Group LLC ($0.33M), Northern Trust Corp ($0.31M), Goldman Sachs Group Inc. ($0.24M), CM Management LLC ($0.23M), Sargent …Stock Screener Earnings Calendar Sectors Nasdaq | CTSO U.S.: Nasdaq Cytosorbents Corp. Watch Set a price target alert After Hours Last Updated: Nov 16, 2023 4:33 p.m. EST Delayed quote $...On Sep 25, 2019, through an announcement, CytoSorbents (NASDAQ:CTSO) highlighted the 'survival benefit' of CytoSorb therapy, their medical device using blood purification technology, in septic ...About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, ...See All Market Activity. News + Insights. CLOSECTSO - Cytosorbents Corp Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)Fiscal Q3 2023 ended 9/30/23. Reported on 11/9/23. Get the latest Cytosorbents Corp (CTSO) real-time quote, historical performance, charts, and other financial information to help you make more...CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Dawson James Small Cap Growth conference at the Wyndham Grand Jupiter at …Cytosorbents Corporation Common Stock (CTSO) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.

About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification.

About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification.

In the previous quarter, Cytosorbents (NASDAQ:CTSO) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. CTSO's actual earnings.CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue PR Newswire PRINCETON, N.J., Jan. 31, 2023 Cumulative CytoSorb treatments surpassed 195,000....Jan 23, 2023 · CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents’ flagship product, CytoSorb®, is approved in the ... Cytosorbents is bordering on breakeven, according to the 4 American Medical Equipment analysts. They expect the company to post a final loss in 2024, before turning a profit of US$5.2m in 2025 ...PRINCETON, N.J., Dec. 29, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood ...Cytosorbents (NASDAQ:CTSO) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends, risk and …Nov 28, 2023 · CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Dawson James Small Cap Growth conference at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, FL on Thursday, October 12th, 2023.

CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically ...PRINCETON, N.J., Jan. 17, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...Nov 24, 2023 · CTSO CytoSorbents Corporation Form 8-K - Current report 0001175151 false 0001175151 2023-09-27 2023-09-27 iso4217:USD xbrli:shares ... Instagram:https://instagram. s nysedoes usaa do pet insurancehiltonstocknat gas stocks May 4, 2023 · By Thomas Kerr, CFA. NASDAQ:CTSO. READ THE FULL CTSO RESEARCH REPORT. CytoSorbents (NASDAQ:CTSO) reported 1st quarter 2023 results on March 2nd with revenue results largely in line with expectations. 1st quarter revenues increased 8.7% to $9.4 million from $8.7 million in the prior year period. GainersCytoSorbents (NASDAQ:CTSO) stock rose 17.3% to $1.29 during Friday's pre-market session. The company's market cap stands at $57.3 million. Tonix ... airline reservations systemmaps stocks March 20, 2023 at 7:38 AM · 3 min read. It is doubtless a positive to see that the Cytosorbents Corporation ( NASDAQ:CTSO) share price has gained some 204% in the last three months. But that is ...The average Cytosorbents stock price prediction forecasts a potential upside of 305.98% from the current CTSO share price of $1.17. What is CTSO's forecast return on assets (ROA) for 2023-2026? (NASDAQ: CTSO) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of -0.01%. best fha lenders in illinois The latest price target for CytoSorbents ( NASDAQ: CTSO) was reported by B. Riley Securities on Thursday, September 7, 2023. The analyst firm set a price target for 4.00 expecting CTSO to rise to ...PRINCETON, N.J., Oct. 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...